The market could potentially see the emergence of new biotech industry leaders. Since the year started, Viking Therapeutics ...

David Fajgenbaum, MD, MBA, MSc Sarcoma Foundation of America SFA's Vision of Hope Award will recognize physician-scientist David ...

Missak Haigentz, MD, highlights some of the significant unmet needs for patients with small cell lung cancer.

This week, J&J JNJ filed for voluntary bankruptcy for the third time in an attempt to bring an end to thousands of lawsuits ...

The agency is considering whether to limit the indications of Keytruda, Opdivo, and Tevimbra to PD-L1-positive patients amid testing uncertainties.

Zymeworks is awaiting key regulatory decisions for zanidatamab, with potential EU and China approvals following. Read more ...

By way of two resoundingly consistent votes, members of an FDA advisory committee agreed that PD-1 inhibitors do not have a favorable risk/benefit profile for gastroesophageal cancers with low PD-L1 ...

Olomorasib with pembrolizumab in the first-line showed a 77% overall response rate in patients with KRAS G12C–mutated ...

APP, MMYT, POWL, NVDA, and TGTX outperformed BTC's approximately 151% gain over the last year from September 27th, 2023, to ...

An adult patient with pulmonary arterial hypertension (PAH) and metastatic lung adenocarcinoma showed significant clinical ...

New data show Talvey’s potential in multiple myeloma drug combinations. Elsewhere, AbbVie got more positive Parkinson’s drug ...